Strumento inattivo

Altre lingue Xenetic Biosciences Inc Other OTC

Azioni

US9840151073

Prezzo di chiusura Other OTC Altri mercati azionari
- ^USD	-

22/05	Xenetic Biosciences, Inc. annuncia le dimissioni del management	CI
22/05	Xenetic Biosciences, Inc. annuncia il cambio dell'Amministratore Delegato	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Xenetic Biosciences, Inc. Announces Management Resignations	22/05
Xenetic Biosciences, Inc. Announces Chief Executive Officer Changes	22/05
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
CLS Therapeutics Discloses its Views on Xenetic Biosciences	18/03
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of Its DNase-Based Oncology Platform	17/01
Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Xenetic Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23
XENC BIOS : HC Wainwright de acheteur à neutre sur le titre	16/05/23
Xenetic Biosciences to Implement 1-for-10 Reverse Split	12/05/23
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23
Xenetic Biosciences, The Scripps Research Institute Enter Into Research Collaboration	11/04/23
Xenetic Biosciences, Inc. Announces the Appointment of Jonathan Spicer to its Scientific Advisory Board	16/11/22
Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/11/22
Xenetic Biosciences, Inc. Appoints Allan Tsung, to Its Scientific Advisory Board	04/10/22
Xenetic Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11/08/22
Xenetic Biosciences, VolitionRx to Develop Adoptive Cell Therapies to Treat Cancer	02/08/22
Xenetic Biosciences Signs Manufacturing Deal With Catalent Unit for Cancer Platform	07/07/22
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	12/05/22
XENETIC BIOSCIENCES, INC. : HC Wainwright toujours positif	02/05/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Xenetic Biosciences Inc Other OTC

Azioni

US9840151073

Altre lingue

Filtri